Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125558222 | 12555822 | 2 | F | 20160817 | 20160714 | 20160818 | PER | PHEH2016US017147 | NOVARTIS | 0.00 | M | Y | 0.00000 | 20160818 | MD | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125558222 | 12555822 | 1 | PS | EXELON PATCH | RIVASTIGMINE | 1 | Transdermal | 13.3 MG, QD(PATCH 10CM2) | U | 4345A | 22083 | 13.3 | MG | TRANS-THERAPEUTIC-SYSTEM | QD | ||||
| 125558222 | 12555822 | 2 | SS | NAMENDA | MEMANTINE HYDROCHLORIDE | 1 | Unknown | U | 0 | ||||||||||
| 125558222 | 12555822 | 3 | C | VITAMIN D | CHOLECALCIFEROL | 1 | Unknown | U | 0 | ||||||||||
| 125558222 | 12555822 | 4 | C | BUSPIRONE | BUSPIRONE HYDROCHLORIDE | 1 | Unknown | U | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 125558222 | 12555822 | 1 | Product used for unknown indication |
| 125558222 | 12555822 | 2 | Product used for unknown indication |
| 125558222 | 12555822 | 3 | Product used for unknown indication |
| 125558222 | 12555822 | 4 | Product used for unknown indication |
Outcome of event
| no results found |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 125558222 | 12555822 | Product adhesion issue |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |